Skip to content

13F-HR filed by Paradigm Biocapital Advisors LP

Paradigm Biocapital Advisors LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 18:15:53 UTC, with 30 holding rows worth $5,028,958,519.

Accession
0001855655-26-000020
Filed
2026-11-16
Accepted by EDGAR
Ingested
Source
EDGAR live feed

Original filing

13F report for Q3 2026

A holdings report, 30 entries on the cover page, a total value of $5,028,958,519 stated on the cover page (in dollars after the unit check, H1), rows summing to $5,028,958,519 with VALUE read as dollars as filed, 13F file number 028-21950. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
REVOLUTION MEDICINES INC COM76155X100Stock6,219,323$1,276,578,239dollars as filed
GENMAB A/S372303206Ordinary Shares, nominal value DKK 1 per share14,136,472$504,318,639dollars as filed
EDGEWISE THERAPEUTICS INC28036F105COM10,778,665$437,613,799dollars as filed
SPYRE THERAPEUTICS INC00773J202COM NEW4,457,450$396,846,774dollars as filed
INSMED INC COM PAR $.01457669307Stock2,695,977$307,718,815dollars as filed
MBX BIOSCIENCES INC COM55287L101Stock3,772,885$221,166,519dollars as filed
ORUKA THERAPEUTICS INC COM687604108Stock2,493,507$207,684,198dollars as filed
BELITE BIO INC07782B104CMN1,142,123$193,955,328dollars as filed
TARSUS PHARMACEUTICALS INC87650L103COMMON STOCK2,301,375$180,911,089dollars as filed
TANGO THERAPEUTICS INC87583X109COM6,961,546$173,690,573dollars as filed
VIRIDIAN THERAPEUTICS INC92790C104COM8,257,672$170,025,466dollars as filed
BRIDGEBIO PHARMA INC10806X102COM2,347,850$154,488,530dollars as filed
VAXCYTE INC COM92243G108Stock2,142,852$121,928,279dollars as filed
ERASCA INC COM29479A108Stock7,998,257$117,254,448dollars as filed
JADE BIOSCIENCES INC008064206COM NEW6,053,268$85,048,415dollars as filed
TYRA BIOSCIENCES INC90240B106COMMON STOCK3,510,360$76,771,573dollars as filed
OLEMA PHARMACEUTICALS INC68062P106COM8,720,576$75,345,777dollars as filed
Obsidian Therapeutics, Inc.67448A106Common Stock, $0.0001 par value per share4,155,214$57,051,088dollars as filed
STRUCTURE THERAPEUTICS INC COMP86366E106EQUITY1,299,199$40,625,953dollars as filed
ACHIEVE LIFE SCIENCES INC004468500COMMON STOCK4,951,856$40,060,515dollars as filed
VERADERMICS INC922967104COMMON STOCK310,060$37,588,574dollars as filed
ASSEMBLY BIOSCIENCES INC045396207COMMON STOCK1,553,748$36,497,541dollars as filed
ORIC PHARMACEUTICALS INC68622P109COM1,505,769$20,282,708dollars as filed
KORSANA BIOSCIENCES INC23255M303COMMON STOCK613,914$19,645,248dollars as filed
EDITAS MEDICINE INC28106W103COM7,575,140$19,468,110dollars as filed
HEMAB THERAPEUTICS HLDGS INC423494103COM SHS629,347$19,409,061dollars as filed
VOR BIOPHARMA INC929033207COMMON STOCK889,575$16,973,091dollars as filed
KARDIGAN INC485925101CMN900,000$13,275,000dollars as filed
TCGX ACQUISITION CORPG8708J109COM300,000$3,753,000dollars as filed
INVENTIVA SA46124U107ADS808,176$2,982,169dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001855655-26-000020this filing2026-11-16